Galantamine Executive Function in Parkinson's Disease

Status unconfirmed · Not applicable

Conditions studied: Parkinson's Disease

In brief

The aim of the study is to determine whether galantamine stabilizes or improves thinking abilities in individuals with Parkinson's disease. Individuals included in the study have minor complaints about thinking such as problems with concentration or memory but do not have dementia. This medication has been shown to have a positive effect on stabilizing memory in individuals with Alzheimer's disease. It is FDA approved for use in elderly individuals with Alzheimer's disease. It is hypothesized that galantamine will stabilize or improve executive and attentional functions in individuals with Parkinson's.

Key facts

Study ID

NCT00211588

Run by

Memorial Hospital of Rhode Island

People needed

90

Starts

2004-06-01

Expected to finish

2007-05-01

Last updated by the study team

2007-05-07

Who can join

Age: 60 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Idiopathic Parkinson's Disease

You may not qualify if…

• dementia, depression, cardiac disease, gastrointestinal disease

Where it is running

• Memorial Hospital of RI — Pawtucket, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.